Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TT-OAD2 free base has the potential for diabetes treatment. TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 mg | Inquiry | Inquiry | |
500 mg | Inquiry | Inquiry |
Description | TT-OAD2 free base has the potential for diabetes treatment. TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. |
Targets&IC50 | GLP-1 receptor:(EC50)5 nM |
In vitro | TT-OAD2 (0-10 μM) inhibits GLP-1- and oxyntomodulin-mediated cAMP, calcium, pERK1/2 and β-arrestin responses in a concentration-dependent manner in HEK293A cells. |
In vivo | TT-OAD2 ?treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice. |
Molecular Weight | 856.83 |
Formula | C50H47Cl2N3O6 |
CAS No. | 1246826-07-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TT-OAD2 free base 1246826-07-2 Others TT OAD2 free base TT-OAD2 TT-OAD-2 free base TTOAD2 free base inhibitor inhibit